Be On Top Of Pain Monitoring In Dogs With Vétoquinol's New Client Specific Outcome Measures Form

Picture shows the outside cover of a Client Specific Outcome Measures for Canine Chronic Pain pad It is widely accepted that all mammals experience pain¹. Under treatment is a big issue and it even occurs in humans as demonstrated by the recent release of new guidelines in treating human pain by NICE which comments, ‘evidence suggests that pain caused by advanced disease remains under-treated’. Veterinary medicine faces a harder task in recognising and treating pain effectively as it relies on behaviour rather than verbal communication. In human medicine, Client Specific Outcome Measures have been used to assess treatment strategies focussing on identifying the degree of difficulty performing daily tasks on an individual patient to patient basis. After the launch of Cimalgex - a new reference in NSAIDs, Vetoquinol has developed a pain monitoring system along similar lines which can be used by vets and owners to measure pain over time and assess different treatment strategies in dogs. Robert Simpson, Product Manager for Cimalgex comments, “The objective assessment of clinical outcomes are a continuing challenge in veterinary medicine; this is particularly true in chronic painful conditions such as osteoarthritis. Use of our Client Specific Outcome Measures form will allow vets and pet owners to more efficiently assess treatment to ensure that the patient is receiving appropriate analgesia. The form can be adapted to give bespoke outcome measures which are agreed in consultation with the owners. This activity will increase interaction with pet owners and could increase loyalty to the practice; it could also be really useful in geriatric clinics etc as a method of assessing pain outside of consultations in practices.” To find out more or to request a monitoring pad for your practice please contact your Vetoquinol Territory Manager or call 01280 825424. 1. Recognition and quantification of pain in small animals – an introduction. James Hunt BVetMed CertVA MRCVS. http://www.ava.eu.com/wp-content/uploads/2010/10/pain-scoring-FINAL-PDF.pdf Cimalgex is a non-steroidal anti-inflammatory drug (NSAID) which contains Cimicoxib (POM-V). Cimicoxib under licence from PALAU PHARMA, Spain. EU2/10/119/001-012. Cimalgex is licensed for the treatment of pain and inflammation associated with osteoarthritis, and the management of peri-operative pain due to orthopaedic or soft tissue surgery, in dogs. For further information on canine pain please visit www.cimydog.co.uk and for further information on Cimalgex please contact Vetoquinol directly.

More from

• IVC Evidensia assembles expert team to run new £10m referral hospital
• Home delivery service can increase pet health plan sign-ups by 25%
• Research reveals vital clues to help fight anthelmintic resistance
• Lifetime Achievement Award recognises Harrogate vet’s dedication to improving the health and welfare of rabbits
• Bake sale at Leicestershire vet practice for good cause